Hematologic Malignancies
Conference Coverage
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
Conference Coverage
Neoadjuvant immunotherapy combo produces high response rate in melanoma
News
Circulating miRNA could be a potential biomarker for early diagnosis of MM
A meta-analysis found that using circulating microRNAs had high sensitivity and specificity in the early diagnosis of multiple myeloma.
News
Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia
The presence of “many or very many nevi [moles]” was particularly associated with the risk of CLL.
Conference Coverage
Immunotherapy for ALL: Roles emerge in R/R disease, MRD+ disease
“Another very exciting development is that these immunotherapies are now demonstrating efficacy and increased tolerability over chemotherapy in...
Conference Coverage
VTEs tied to immune checkpoint inhibitor cancer treatment
Retrospective analysis hints that cancer patients have an elevated risk for venous thromboembolism following treatment with an immune checkpoint...
Article
Using telehealth to deliver palliative care to cancer patients
Dr. Alan Lyss discusses the use of telehealth for palliative cancer care, including results from the REACH PC trial.
Conference Coverage
Home care for bortezomib safe and reduces hospital visits in myeloma patients
News
Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients
News
Beat AML: Precision medicine strategy feasible, superior to SOC for AML
"The study is changing significantly the way we look at treating patients with AML, showing that precision medicine ... can improve short- and...